MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Home・Listă Acțiuni・Fate Therapeutics Inc

Fate Therapeutics Inc

Închisă

SectorSănătate

1.2 15.38

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

1.04

Maxim

1.21

Indicatori cheie
By Trading Economics
Venit	1.8M -32M
Vânzări	-166K 1.7M
Marjă de profit	-1,852.384
Angajați	181
EBITDA	7.9M -29M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+341.9% upside

Dividende
By Dow Jones
Următoarele câștiguri	3 mar. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-2.3M 123M
Deschiderea anterioară	-14.18
Închiderea anterioară	1.2

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

0.9101 / 1.14 Suport & Rezistență

Fate Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 ian. 2026, 23:29 UTC

Acțiuni populare

Stocks to Watch: Atossa Therapeutics, Union Pacific

16 ian. 2026, 22:48 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- 2nd Update

16 ian. 2026, 22:43 UTC

Achiziții, Fuziuni, Preluări

Union Pacific: Additional Information Requested to Be Provided to Surface Transportation Board

16 ian. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- Update

16 ian. 2026, 21:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Tech, Media & Telecom Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Auto & Transport Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 ian. 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

16 ian. 2026, 21:48 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Union Pacific, Norfolk Southern Market Share Ruled as Faulty -- Market Talk

16 ian. 2026, 21:41 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Union Pacific, Norfolk Southern Deal Rejection Leaves Questions -- Market Talk

16 ian. 2026, 21:38 UTC

Achiziții, Fuziuni, Preluări

Rail Regulator Sends $71.5 Billion Union Pacific-Norfolk Southern Deal Back for Redo -- WSJ

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Include 'Projected Market Shares' as Required

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Include Certain Schedules, Documents Expressly Made Part of Merger Agreement

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Union Pacific, Norfolk Southern Application Doesn't Contain Certain Information Required by Regulations

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

STB: Application Rejected Without Prejudice to Union Pacific, Norfolk Southern Refiling Revised Application Remedying Deficiencies

16 ian. 2026, 21:30 UTC

Achiziții, Fuziuni, Preluări

Surface Transportation Board: Union Pacific, Norfolk Southern Major Merger Application Filed Dec. 19 Incomplete

16 ian. 2026, 20:44 UTC

Câștiguri

5 Takeaways From This Season's Wealth Management Earnings -- Barrons.com

16 ian. 2026, 20:42 UTC

Market Talk

Oil Futures Post Fourth Straight Weekly Gain -- Market Talk

16 ian. 2026, 20:28 UTC

Market Talk

U.S. Natural Gas Slips Ahead of Long Weekend -- Market Talk

16 ian. 2026, 19:12 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Netflix Could Comment on Structure of Warner Bid During 4Q Results -- Market Talk

16 ian. 2026, 18:53 UTC

Market Talk

Global Crude Supply Enough to Absorb Any Iran Disruption -- Market Talk

16 ian. 2026, 18:41 UTC

Market Talk

Netflix's Ad Business Seen as Primary Revenue Driver in 2026 -- Market Talk

16 ian. 2026, 18:31 UTC

Market Talk

U.S. Oil Rig Count Rises By 1 to 410 -- Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 ian. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

16 ian. 2026, 17:03 UTC

Market Talk

Global Equities Roundup: Market Talk

16 ian. 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

16 ian. 2026, 16:32 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Sanofi Needs Dealmaking to Offset Pipeline Disappointments -- Market Talk

16 ian. 2026, 16:20 UTC

Market Talk

Global Equities Roundup: Market Talk

Comparație

Modificare preț

Fate Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

341.9% sus

Prognoză pe 12 luni

Medie 4.64 USD 341.9%

Maxim 8 USD

Minim 2 USD

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruFate Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 9 analiști care au acordat evaluări ale acțiunilor Fate Therapeutics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

0.9101 / 1.14Suport & Rezistență

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.